Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.54 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | MET | P08581 | 3/20 | 0.54 |
| ▸ | TEK | Q02763 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.47 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826950 | 0.83 | EGFR (0.60) | PDGFRAPDGFRBFGFR2EGFR | |
| SCHEMBL8145365 | 0.81 | HTR1A (0.61) | KDRAURKAMETTEKAURKB | |
| SCHEMBL25466495 | 0.80 | FGFR2 (0.60) | KDRAURKAMETTEKAURKB | |
| SCHEMBL29043514 | 0.79 | FGFR2 (0.54) | KDRAURKAMETTEKAURKB | |
| SCHEMBL22435917 | 0.77 | KDR (0.57) | KDRAURKAMETTEKAURKB | |
| SCHEMBL14540594 | 0.76 | KDR (0.57) | KDRAURKAMETTEKAURKB | |
| SCHEMBL29043517 | 0.75 | FGFR2 (0.53) | KDRAURKAMETTEKAURKB | |
| SCHEMBL25719229 | 0.74 | GAK (0.49) | KDRAURKAMETTEKAURKB | |
| SCHEMBL30131538 | 0.74 | KDR (0.71) | KDRAURKAMETTEKAURKB | |
| SCHEMBL22435918 | 0.74 | FGFR2 (0.62) | KDRAURKAMETTEKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219929-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | KDR 37/4885AURKA 248/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.